Literature DB >> 7999340

Quality of life in Alzheimer disease.

M P Lawton1.   

Abstract

Quality of life (QOL) in dementing illness comprises the same areas as in people in general. Domains of QOL in patients with Alzheimer disease (AD) include competent cognitive functioning, the ability to perform activities of daily living and to engage in meaningful time use and social behavior, and a favorable balance between positive emotion and absence of negative emotion. Dementing illness can strip the person of normal indicators of personhood. Formal assessment of such QOL indicators can counteract the tendency to view QOL as irrelevant to dementing illness. A preliminary report of ongoing research to evaluate a special care unit for patients with AD includes findings on measuring positive behaviors and both positive and negative emotion. Emotions judged from direct observation showed promising reliability and validity. Thus, it may be possible to assess the preferences, aversions, and response to interventions of dementia patients even when the patients cannot report their evaluations.

Entities:  

Mesh:

Year:  1994        PMID: 7999340

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  48 in total

Review 1.  Finding a useful conceptual basis for enhancing the quality of life of nursing home residents.

Authors:  D L Gerritsen; N Steverink; M E Ooms; M W Ribbe
Journal:  Qual Life Res       Date:  2004-04       Impact factor: 4.147

2.  A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia.

Authors:  Ann Kolanowski; Donna M Fick; Judy Campbell; Mark Litaker; Malaz Boustani
Journal:  J Am Med Dir Assoc       Date:  2009-01-09       Impact factor: 4.669

3.  Critical evaluation of self-rated quality of life in mild cognitive impairment and Alzheimer's disease--further evidence for the impact of anosognosia and global cognitive impairment.

Authors:  M Berwig; H Leicht; H J Gertz
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

4.  Cross-cultural adaptation and psychometric validation of a Spanish version of the Quality of Life in Late-Stage Dementia Scale.

Authors:  Josep Garre-Olmo; Xènia Planas-Pujol; Secundino López-Pousa; Myron F Weiner; Antoni Turon-Estrada; Dolors Juvinyà; David Ballester; Joan Vilalta-Franch
Journal:  Qual Life Res       Date:  2010-02-03       Impact factor: 4.147

Review 5.  A review of quality of life in Alzheimer's disease. Part 1: Issues in assessing disease impact.

Authors:  M D Walker; S S Salek; A J Bayer
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

6.  Generic quality of life assessment in dementia patients: a prospective cohort study.

Authors:  Claudia Schiffczyk; Barbara Romero; Christina Jonas; Constanze Lahmeyer; Friedemann Müller; Matthias W Riepe
Journal:  BMC Neurol       Date:  2010-06-20       Impact factor: 2.474

7.  Evaluation of the validity and reliability of the Alzheimer Disease-related Quality of Life Assessment Instrument.

Authors:  Judith D Kasper; Betty S Black; Andrew D Shore; Peter V Rabins
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jul-Sep       Impact factor: 2.703

8.  Daytime observed emotional expressions of people with dementia.

Authors:  Kyung Hee Lee; Donna L Algase; Eleanor S McConnell
Journal:  Nurs Res       Date:  2013 Jul-Aug       Impact factor: 2.381

9.  The impact of subject/respondent characteristics on a proxy-rated quality of life instrument for the Japanese elderly with dementia.

Authors:  N Yamamoto-Mitani; T Abe; Y Okita; K Hayashi; C Sugishita; K Kamata
Journal:  Qual Life Res       Date:  2004-05       Impact factor: 4.147

10.  Quality of life as an outcome in Alzheimer's disease and other dementias--obstacles and goals.

Authors:  Matthias W Riepe; Thomas Mittendorf; Hans Förstl; Lutz Frölich; Martin Haupt; Reiner Leidl; Christoph Vauth; Matthias Graf von der Schulenburg
Journal:  BMC Neurol       Date:  2009-08-25       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.